Prevalence and human papillomavirus (HPV) genotype distribution in Suzhou, China

ABSTRACT Persistent infection with high-risk human papillomavirus (HR-HPV) is a known pathogenic factor of cervical cancer. To develop scientific guidance for cervical cancer screening and HPV vaccination, we analyzed HPV genotypes in Suzhou City, China. This study utilized data from the cervical cancer screening project in Suzhou from 2016 to 2021. A total of 444,471 female residents who voluntarily underwent HPV testing were included in the study. The overall HR-HPV prevalence was 10.2%. The three most common HR-HPV genotypes were HPV52 (2.81%), HPV58 (1.64%), and HPV16 (1.46%). The rate of HPV infection increased with age. Having a junior school education or higher was a protective factor compared to having an education level below junior school. The overall HPV infection rate showed a downwards trend from 2016 to 2021. HPV16 exhibited the fastest annual decline rate, followed by HPV18. As the severity of cervical intraepithelial neoplasia increases, the detection rate of HPV infection significantly increased. In conclusion, in addition to cervical cancer screening, it is important to pay attention to health promotion and education for low-educated women aged 45–59. Considering the distribution of HPV genotypes, prioritizing the administration of high-valency HPV vaccines to local seventh-grade female students is recommended.

[1]  K. Matsumoto,et al.  Whole-genome analysis of human papillomavirus 67 isolated from Japanese women with cervical lesions , 2022, Virology Journal.

[2]  Xin Fan,et al.  Prevalence and Genotype Distribution of Human Papillomavirus Infection Among 40,613 Women: An Outpatient-Based Population Study in Kunming, Yunnan , 2022, Frontiers in public health.

[3]  M. Poljak,et al.  Cervical cancer screening programmes and age-specific coverage estimates for 202 countries and territories worldwide: a review and synthetic analysis , 2022, The Lancet. Global health.

[4]  Y. Qiao,et al.  Changes in High-Risk HPV Infection Prevalence and Associated Factors in Selected Rural Areas of China: A Multicenter Population-Based Study , 2022, Frontiers in Medicine.

[5]  Xiaohong Lin,et al.  Age‐specific prevalence and genotype distribution of human papillomavirus in women from Northwest China , 2022, Cancer medicine.

[6]  N. Bragazzi,et al.  Effects of the COVID-19 pandemic on sexual functioning and activity: a systematic review and meta-analysis , 2022, BMC Public Health.

[7]  Ruili Sun,et al.  Prevalence and distribution of human papillomavirus genotypes among women attending gynecology clinics in northern Henan Province of China , 2022, Virology Journal.

[8]  Hongbo Wang,et al.  Human papillomavirus prevalence and genotype distribution landscapes in Shannan City, Tibet Tibetan Autonomous Region, China , 2021, Virology Journal.

[9]  Shaowei Wang,et al.  Prevalence characteristics of cervical human papillomavirus genotypes in Nanning, China: A 10‐year survey of 77,756 women from one medical center , 2021, Journal of medical virology.

[10]  Chengquan Zhao,et al.  Nationwide Prevalence and Genotype Distribution of High-Risk Human Papillomavirus Infection in China. , 2021, American journal of clinical pathology.

[11]  P. Sasieni,et al.  The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study , 2021, The Lancet.

[12]  L. Shen,et al.  Prevalence and genotype distribution of high‐risk human papillomavirus infection among women with cervical cytological abnormalities in Chongqing, China, 2014–2020 , 2021, Diagnostic cytopathology.

[13]  Yufei Xiao,et al.  Prevalence, characteristics, and distribution of HPV genotypes in women from Zhejiang Province, 2016–2020 , 2021, Virology journal.

[14]  Jie Wu,et al.  Prevalence and Genotype Distribution of Human Papillomavirus Among Healthy Females in Beijing, China, 2016–2019 , 2021, Infection and drug resistance.

[15]  Lixin Wang,et al.  Genotype Distribution and Prevalence of Human Papillomavirus Infection in Women in Northern Jiangsu Province of China , 2021, Cancer management and research.

[16]  Wanqing Chen,et al.  Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020 , 2021, Chinese medical journal.

[17]  T. Tan,et al.  Heat maps present the spatial distribution of human papillomavirus infection in Zhejiang Province, China , 2021, Oncology letters.

[18]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[19]  Ying Lu,et al.  Incidence, persistence and clearance of cervical human papillomavirus among women in Guangdong, China 2007-2018: A retrospective cohort study. , 2020, Journal of infection and public health.

[20]  Huan Cheng,et al.  Prevalence and genotype distribution of human papillomavirus among women with cervical lesions in Shenzhen city, China , 2020, Human vaccines & immunotherapeutics.

[21]  N. Xia,et al.  Comparing immunogenicity of the Escherichia coli-produced bivalent human papillomavirus vaccine in females of different ages. , 2020, Vaccine.

[22]  Yunxia Cao,et al.  Impact of the COVID-19 Pandemic on Partner Relationships and Sexual and Reproductive Health: Cross-Sectional, Online Survey Study , 2020, Journal of medical Internet research.

[23]  Hongliang Chen,et al.  Prevalence and genotype distribution of HPV infection among 214,715 women from Southern China, 2012–2018: baseline measures prior to mass HPV vaccination , 2020, BMC Infectious Diseases.

[24]  Yanfang Jiang,et al.  HPV genotypic spectrum in Jilin province, China, where non-vaccine-covered HPV53 and 51 are prevalent, exhibits a bimodal age-specific pattern , 2020, PloS one.

[25]  Jiaqian Wang,et al.  Prevalence and genotype distribution of HPV and cervical pathological results in Sichuan Province, China: a three years surveys prior to mass HPV vaccination , 2020, Virology Journal.

[26]  J. Dillner,et al.  Are 20 human papillomavirus types causing cervical cancer? , 2014, The Journal of pathology.

[27]  M. Schiffman,et al.  Updating the natural history of human papillomavirus and anogenital cancers. , 2012, Vaccine.

[28]  E. Franco,et al.  Epidemiology and burden of HPV infection and related diseases: implications for prevention strategies. , 2011, Preventive medicine.

[29]  J. Berkhof,et al.  Preferential risk of HPV16 for squamous cell carcinoma and of HPV18 for adenocarcinoma of the cervix compared to women with normal cytology in The Netherlands , 2005, British Journal of Cancer.

[30]  E. Feuer,et al.  Permutation tests for joinpoint regression with applications to cancer rates. , 2000, Statistics in medicine.

[31]  Human papillomavirus vaccines: WHO position paper, May 2017-Recommendations. , 2017, Vaccine.

[32]  Who,et al.  Human papillomavirus vaccines: WHO position paper. , 2009, Biologicals : journal of the International Association of Biological Standardization.

[33]  中華人民共和国国家統計局.  China statistical yearbook , 1988 .